Posted by Michael Wonder on 04 Jul 2021
ICER to test principle of fair access to fairly priced pharmaceuticals
2 July 2021 - The controversial approval last month by the FDA of Aduhelm (aducanumab) for patients with early-stage Alzheimer’s disease caught the attention of patient groups, clinicians, policymakers, and market analysts alike.
Priced at $56,000 on an annual basis (wholesale acquisition cost) Aduhelm has the potential to be a mega blockbuster, particularly since millions of Alzheimer’s patients could be eligible for the drug.
